Using PARP1 inhibitors such as olaparib and rituximab, in the presence of TP53 mutations, DNA damage response deficit tumors were shown to be repressed, and increased cytotoxicity was reported in DLBCL cell lines [51]. The gene discussed is PARP1; the disease is diffuse large B-cell lymphoma.